13F Holdings
中文EN

TLSI TriSalus Life Sciences, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1826667 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.4%
TTM net income YoY33.7%
TTM EPS YoY80.7%
Revenue 3-yr CAGR42.5%
Net income 3-yr CAGR—

Margins

Gross margin86.5%
Operating margin-63.0%
Net margin-56.6%
FCF margin-53.3%
EBITDA margin-61.8%

Returns

ROE—
ROA-55.8%
ROIC (approx.)—
Asset turnover0.99x

Leverage & solvency

Liabilities / assets98.8%
Debt / equity47.60x
Current ratio4.22x
Interest coverage-4.92x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$12.88M$11.41M$8.90M$13.21M$11.57M$11.21M$9.17M$8.26M
Cost of revenue$1.78M$1.51M$1.23M$1.76M$1.91M$1.80M$1.50M$1.22M
Gross profit$11.10M$9.90M$7.67M$11.44M$9.66M$9.41M$7.67M$7.04M
R&D expense$3.19M$3.14M$3.22M$2.57M$5.70M$3.67M$3.02M$2.96M
SG&A expense$4.88M$5.16M$5.45M$4.17M$6.13M$5.91M$5.25M$4.66M
Operating income-$7.71M-$9.81M-$8.41M-$3.27M-$9.01M-$7.33M-$7.33M-$7.58M
Interest expense$1.56M$1.49M$1.44M$1.45M$1.46M$1.42M$1.21M$1.07M
Pretax income-$8.85M-$9.18M$1.54M-$9.75M-$10.81M-$8.29M-$10.37M-$10.11M
Income tax$4,000$4,000$4,000$0$5,000-$3,000$5,000-$1,000
Net income-$8.85M-$9.19M$1.54M-$9.75M-$10.81M-$8.29M-$10.38M-$10.11M
EBITDA-$7.58M-$9.68M-$8.28M-$3.15M-$8.85M-$7.17M-$7.16M-$7.39M
EPS (basic)-0.15-0.160.03—-0.96-0.27-0.39—
EPS (diluted)-0.15-0.160.03—-0.96-0.27-0.39—
Weighted avg. shares (diluted)58.47M58.30M52.31M—43.06M32.90M28.53M—
Balance sheet
Cash & equivalents$41.06M$46.29M$56.55M$20.44M$23.04M$26.84M$13.35M$8.88M
Receivables$6.13M$6.46M$5.21M$6.56M$5.00M$5.57M$5.45M$5.09M
Inventory$4.64M$4.21M$3.78M$3.08M$3.28M$3.81M$4.16M$4.05M
Current assets$54.90M$59.74M$68.14M$32.24M$33.33M$38.08M$25.10M$20.67M
PP&E, net$1.83M$1.84M$1.94M$1.81M$1.83M$1.71M$1.97M$1.67M
Total assets$57.56M$62.45M$70.98M$35.33M$36.46M$41.32M$28.62M$23.97M
Current liabilities$13.01M$11.17M$11.79M$11.50M$10.91M$9.32M$11.75M$10.23M
Long-term debt$32.37M$33.06M$33.08M$33.05M$32.76M$32.27M$31.70M$22.08M
Total debt$32.37M$33.06M$33.08M$33.05M$32.76M$32.27M$31.70M$22.08M
Total liabilities$56.88M$55.90M$58.17M$69.19M$63.19M$60.74M$62.99M$49.87M
Shareholders' equity$680,000$6.55M$12.81M-$33.86M-$26.73M-$19.42M-$34.37M-$25.89M
Net debt-$8.69M-$13.22M-$23.47M$12.61M$9.73M$5.43M$18.35M$13.21M
Shares outstanding61.66M61.47M61.41M50.00M49.89M37.98M32.27M31.28M
Cash flow statement
Operating cash flow-$5.28M-$10.13M-$6.48M-$2.48M-$3.71M-$7.32M-$4.50M-$5.71M
Capital expenditure$90,000$82,000$141,000$41,000$216,000-$93,000$754,000$50,000
Free cash flow-$5.37M-$10.21M-$6.62M-$2.52M-$3.92M-$7.23M-$5.25M-$5.76M
Investing cash flow-$90,000-$82,000-$141,000-$41,000-$176,000$93,000-$714,000-$50,000
Financing cash flow$134,000-$54,000$42.38M$277,000$82,000$20.72M$9.69M$2.99M
Depreciation & amortization$129,000$136,000$135,000$126,000$163,000$165,000$172,000$193,000
Stock-based compensation$2.83M$2.62M$2.47M$2.20M$3.42M$1.89M$1.62M$1.70M

Free plan shows the latest 8 periods; Pro shows all 24 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.